A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.
Key facts
- Registry number
- NCT07361562
- Stage of testing
- Phase 1
- Conditions studied
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression, Non-Small Cell Lung Cancer, HER2
Where it is running
This trial lists 15 sites.
-
Arizona
- HonorHealth Research Institute (Scottsdale)
- Mayo Scottsdale (Scottsdale)
-
Connecticut
- Yale Cancer Center (New Haven)
-
Florida
- Mayo Jacksonville (Jacksonville)
-
Illinois
- Northwestern University (Chicago)
-
Louisiana
- LSU Health Sciences Center School of Medicine (New Orleans)
-
Michigan
- START Midwest (Grand Rapids)
-
Minnesota
- Mayo Rochester (Rochester)
-
Missouri
- Washington University School of Medicine - Siteman Cancer Center (St Louis)
-
New York
- START NY Long Island (Lake Success)
- NYU Langone (New York)
-
Tennessee
- Tennessee Oncology (Nashville)
-
Texas
- NEXT Oncology Texas (Austin)
-
Utah
- START Mountain Region (West Valley City)
-
Virginia
- NEXT Oncology Virginia (Fairfax)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.